Purpose: We report the final analysis of JVDL (NCT02789345), which examined the combination of the EGFR tyrosine kinase inhibitor (TKI) osimertinib plus the VEGFR2-directed antibody ramucirumab in patients with T790M-positive -mutant non-small cell lung cancer (NSCLC).
Patients And Methods: This open-label, single-arm phase I study enrolled patients with T790M-positive NSCLC, who had progressed following EGFR TKI but were third-generation EGFR TKI-naïve. A dose-limiting toxicity (DLT) period with as-needed dose deescalation was followed by an expansion cohort. Patients received daily oral osimertinib and intravenous ramucirumab every 2 weeks until progression or discontinuation.
Results: Twenty-five patients were enrolled. No DLTs were observed. Median follow-up time was 25.0 months. Common grade 3 or higher treatment-related adverse events (TRAE) were hypertension (8%) and platelet count decreased (16%); grade 5 TRAE (subdural hemorrhage) occurred in 1 patient. Patients with ( = 10) and without central nervous system (CNS) metastasis ( = 15) had similar safety outcomes. Five patients remain on treatment. Objective response rate (ORR) was 76%. Median duration of response was 13.4 months [90% confidence interval (CI): 9.6-21.2]. Median progression-free survival (PFS) was 11.0 months (90% CI: 5.5-19.3). Efficacy was observed in patients with and without CNS metastasis (ORR 60% and 87%; median PFS 10.9 and 14.7 months, respectively). Exploratory biomarker analyses in circulating tumor DNA suggested that on-treatment loss of EGFR Exon 19 deletion or L858R mutations, detectable at baseline, correlated with longer PFS, but on-treatment loss of T790M did not. Emergent genetic alterations postprogression included C797S, MET amplification, and EGFR amplification.
Conclusions: Ramucirumab plus osimertinib demonstrated encouraging safety and antitumor activity in T790M-positive -mutant NSCLC..
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793125 | PMC |
| http://dx.doi.org/10.1158/1078-0432.CCR-20-1690 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.
Lung Cancer
November 2024
Department of Genome Biology, Kindai University, Faculty of Medicine, Japan.
Article Synopsis
- The study investigates the combined efficacy of afatinib, an EGFR-tyrosine kinase inhibitor, and bevacizumab, a VEGF inhibitor, in patients with EGFR-mutant non-small cell lung cancer who have become resistant to osimertinib.
- Out of 28 enrolled patients, the combination treatment resulted in a 17.9% response rate and an overall disease control rate of 78.6%, with a median duration of response of 9 months.
- The analysis of rebiopsied samples identified various resistance mechanisms, revealing that certain mutations (like C797S and uncommon EGFR mutations) were associated with better responses, while patients with T790M
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.
BMC Med
October 2024
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Article Synopsis
- Lazertinib is a new type of medicine that helps treat a kind of lung cancer called NSCLC, especially for people whose cancer got worse after other treatments.
- In a study with 78 patients, those taking lazertinib lived for an average of about 39 months and had good survival rates at 1, 2, and 3 years.
- The study found that checking for certain cancer genes in the blood can help predict how well patients will respond to lazertinib treatment.
Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure.
Oncol Lett
November 2024
Department of Thoracic Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian 350014, P.R. China.
Treatment options for epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC) following tyrosine kinase inhibitor (TKI) failure are limited, and platinum-based chemotherapy remains the main treatment. The development of effective immunotherapy for this disease has been challenging. In the present study, 37 patients with EGFR-mutant advanced NSCLC who were treated with programmed cell death-1 (PD-1) inhibitor-based combinations after TKI failure were reviewed.
View Article and Find Full Text PDFDevelopment and validation of a deep learning-based model to predict response and survival of T790M mutant non-small cell lung cancer patients in early clinical phase trials using electronic medical record and pharmacokinetic data.
Transl Lung Cancer Res
April 2024
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Article Synopsis
- The T790M mutation in the epidermal growth factor receptor is important for predicting if certain lung cancer treatments will work, but not all patients with this mutation respond well to those treatments.* -
- A new method called "Mixture-of-experts" (MoE) combines different small models to spot patterns in T790M-mutated lung cancer patients, aiming to better predict how well they will respond to treatments.* -
- Research showed that using this new method helped predict treatment responses with good accuracy, and patients at low risk of not responding to treatment had a longer time without disease progression.*
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC.
Ther Adv Med Oncol
January 2024
Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taipei, Taiwan.
Background: Substitution of methionine for threonine at codon 790 (T790M) of epidermal growth factor receptor (EGFR) represents the major mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in -mutant non-small-cell lung cancer. We determined the prognostic impact and association of secondary T790M mutations with the outcomes of osimertinib and chemotherapy.
Methods: Patients (n = 460) progressing from first-line EGFR-TKI treatment were assessed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!